AstraZeneca & Pangaea Partner to Advance AI-Powered Precision Healthcare
London and South San Francisco, 2nd December 2025: Pangaea Data (Pangaea) today announced a multi‑year strategic collaboration with AstraZeneca, to make AI-driven clinical decision-making available at scale, and improve how patients are identified, diagnosed, treated and connected to existing therapies and clinical trials.
As part of the collaboration, AstraZeneca and Pangaea will co‑develop an enterprise‑grade platform that fuses large‑scale clinical, imaging, genomic, pathology and real‑world data using the latest breakthroughs in generative and predictive AI from Microsoft.
Building an engine for multimodal insight
Pangaea already brings deep experience in deploying AI and advanced patient-intelligence platforms worldwide. Its clinical‑grade systems, which follow clinical guidelines and are validated by clinicians, are being used to close care gaps and optimize patient outcomes across multiple chronic conditions, oncology and rare diseases. This includes Chronic Kidney Disease (CKD), Chronic Obstructive Pulmonary Disease (COPD), asthma, metastatic breast cancer and gastric cancer.
This experience and expertise, coupled with the reach and impact of AstraZeneca will enable:
- Multimodal Models and Applications: AstraZeneca and Pangaea’s research teams will train and validate their existing multimodal models to further support clinical trials and point‑of‑care decisions.
- Patient-Intelligence Layer: Pangaea’s platform will apply its clinical-grade AI to discover untreated, misdiagnosed, and under-treated patients at scale, and generate cohorts and insights to inform physicians for patient management. These platform capabilities and their reach will then be further strengthened by its participation in both the NVIDIA Inception and Microsoft Pegasus programs.
- Ambient Listening and Agentic AI Orchestration: the early collaboration with Microsoft includes plans to connect Pangaea’s systems into existing clinical workflows where it will use ambient listening and agentic AI orchestration to enable real-time, context-aware recommendations at the point of care.
- Compute and Infrastructure: Microsoft Azure’s high‑performance AI super‑computing clusters, powered by NVIDIA’s GPUs and Azure OpenAI Service, will provide the processing capacity to train, deploy and refine multimodal models quickly and securely.
- Data Fabric and Security: Microsoft Fabric and Azure confidential computing will then provide the secure, compliant, privacy-preserving foundation for global data collaboration.
Key Outcomes
- Accelerated Patient Discovery and Clinical Decision Support for clinicians: Pangaea’s platform will support the discovery of eligible patients in real time for precision therapies and clinical trials based on guidelines and respective protocols. The platform’s AI will identify and highlight evidence‑based treatment (or trial) recommendations and real-time insights within electronic health record (EHR) systems and workflows thereby helping clinicians to improve outcomes in a sustainable manner.
- Scalable, Responsible Deployment: Through federated learning, differential privacy, and model‑monitoring, the collaboration allows Pangaea and AstraZeneca to scale innovation responsibly; putting patients first while protecting patient information and delivering care against global regulatory standards.
David Dellamonica, Global Head of Digital Care Pathway Optimization, AstraZeneca said: “This first wave marks a defining moment for precision healthcare and medicines development. By combining our scientific leadership with NVIDIA and Microsoft’s AI capabilities, and enabling real‑world reach through Pangaea Data, we believe this technology will support our aim to transform outcomes for millions of patients.”
David Rhew, MD, Global Chief Medical Officer, Microsoft, said: “At Microsoft, we’re proud to serve as technology enablers for collaborations like this one between Pangaea Data and AstraZeneca. By harnessing the power of secure, scalable AI and cloud infrastructure, we’re helping our customers deliver innovations that advance precision healthcare and enhance patient care.”
Howard Wright, Vice President, Startup Ecosystem, NVIDIA, said: “At NVIDIA, we’re committed to empowering our Inception Startup members as they drive advancements across all verticals. Our collaboration with Pangaea Data exemplifies the impact of collective innovation — by integrating our software libraries into their platform. We’re helping accelerate the pace of discovery in healthcare. We look forward to seeing the difference our partnership will make for patients and the broader ecosystem.”
Vibhor Gupta, PhD, Founder & CEO, Pangaea Data, said: “We are excited to collaborate with AstraZeneca on this mission to transform care by ensuring that patients are connected to life‑changing therapies and trials effectively in a compliant and financially sustainable manner.”
-ENDS –
Contact: pr@pangaeadata.ai
